Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 100mg | $55.00 | $0.55/mg | In stock | Jul 11 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| HY-GHK-R2M6 | Feb 2026 | 99.9% | Janoshik Analytical | Heavy metals | Unverified | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. GHK is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Hydro Research Peptides sell GHK?
Yes — Hydro Research Peptides currently lists GHK in 1 variant starting at $55.00 ($0.55/mg).
Is Hydro Research Peptides's GHK third-party tested?
Yes — Disclosed Labs has indexed 1 Certificate of Analysis for Hydro Research Peptides's GHK, with the most recent showing 99.9% purity. Hydro Research Peptides holds an overall trust grade of C (73/100) across all 140 COAs on file.
What is Hydro Research Peptides's trust grade for GHK?
Hydro Research Peptides has an overall Disclosed Labs trust grade of C (73/100), computed from 140 COAs across all peptides. The most recent GHK COA was issued by Janoshik Analytical.
Where is the cheapest GHK?
As of the latest data, Optima Supply offers GHK at $0.55/mg — compare with Hydro Research Peptides's listing at $0.55/mg. See the full GHK price comparison.
Is GHK legal to buy?
GHK is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
Disclosed Labs